US2009054527A1PendingUtilityA1

Administration of capsaicinoids

Assignee: ALGORXPriority: Dec 18, 2002Filed: Aug 11, 2008Published: Feb 26, 2009
Est. expiryDec 18, 2022(expired)· nominal 20-yr term from priority
A61P 43/00A61K 36/81C07C 231/02A61P 29/00A61K 31/167A61K 31/16A61K 31/5415A61K 31/551A61K 31/165A61K 45/06A61P 25/02A61P 25/00
64
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Disclosed in certain embodiments is a method for relieving pain at a site in a human or animal in need thereof, comprising administering by injection or infiltration, a dose of a capsaicinoid and coadministering a vasodilator.

Claims

exact text as granted — not AI-modified
1 . A method for relieving pain at a site in a human or animal in need thereof, comprising: administering at a discrete painful site in a human or animal in need thereof a single injectable or implantable dose of a capsaicinoid in an amount effective to denervate said discrete site without eliciting an effect outside the discrete location and to attenuate pain emanating from said site, said effective dose being from about 1 mcg to about 5000 mcg of capsaicin or a therapeutically equivalent dose of a capsaicinoid other than capsaicin; and co-administering an amount of a vasodilator. 
   
   
       2 . The method of  claim 1 , wherein the non-anesthetic vasodilator is in the same formulation as the capsaicinoid. 
   
   
       3 . The method of  claim 1 , wherein the vasodilator is in a different formulation than the capsaicinoid. 
   
   
       4 . The method of  claim 1 , wherein the vasodilator is administered by a different route than the capsaicinoid. 
   
   
       5 . The method of  claim 1 , wherein the vasodilator is administered by the same route as the capsaicinoid. 
   
   
       6 . The method of  claim 1 , wherein the vasodilator is administered orally, via implant, parenterally, sublingually, rectally, topically, or via inhalation. 
   
   
       7 . The method of  claim 3 , wherein the administration of the capsaicinoid and the coadministration of the vasodilator have overlapping durations of effect. 
   
   
       8 . The method of  claim 1 , wherein the vasodilator is a nitrate vasodilator. 
   
   
       9 . The method of  claim 1 , wherein the vasodilator is selected from the group consisting of clonitrate, erythrityl tetranitrate, isobutyl nitrate, isoidide dinitrite or mononitrite, isomannide dinitrite or mononitrite, isosorbide dinitrate or mononitrate, mononitrate, mannitol hexanitrate, nitroglycerin, pentaeryhtritol tetranitrate, pentaeryhtritol trinitrate or dinitrite or mononitrite, pentrinitrol, propatyl nitrate, sodium nitroprusside, trolnitrate phosphate, 1,3-propane dinitrite, 1,7-heptane dinitrite, cyclohexylmethyl nitrite, 2-phenylethyl nitrite, 3-chloro-2,2 dimethylpropyl nitrite, tert-amyl nitrite, 2-methyl-2-hexyl nitrite, hexyl nitrite, 2-methyl-1,3-propane dinitrite, 2,2,dimethyl-1,3-propane dinitrite, 2-methyl-2-propyl-1,3-propane dinitrite, 3-hexyl nitrite, octyl nitrite, 4-methyl-2-pentyl nitrite, 4-methyl-1-pentyl nitrite, 2-heptyl nitrite, 3-octyl nitrite, 2-methyl-2-pentyl nitrite, 5-methyl-2-hexyl nitrite, 6-methyl-2-heptyl nitrite pharmaceutically acceptable salts thereof and mixtures thereof. 
   
   
       10 . The method of  claim 8 , wherein the vasodilator is administered orally. 
   
   
       11 . The method of  claim 8 , wherein the vasodilator is administered parenterally. 
   
   
       12 . The method of  claim 1 , wherein the vasodilator is in an effective amount to diffuse the capsaicinoid throughout the desired site of action. 
   
   
       13 . The method of  claim 1 , further comprising administering a local anesthetic to the human or animal. 
   
   
       14 . The method of  claim 13 , wherein the local anesthetic is administered at a site distal to the administration of the capsaicinoid to provide a regional blockade. 
   
   
       15 . The method of  claim 14 , further comprising administering a vasoconstrictor with the local anesthetic to prolong the duration of effect of the local anesthetic. 
   
   
       16 . The method of  claim 1 , wherein said dose of capsaicinoid is administered in a pharmaceutically acceptable vehicle for injection or implantation. 
   
   
       17 . The method of  claim 16 , wherein said pharmaceutically acceptable vehicle is an aqueous vehicle is selected from the group consisting of Sodium Chloride Injection, Ringers Injection, Isotonic Dextrose Injection, Sterile Water Injection, Dextrose, Lactated Ringers Injection and any combinations or mixtures thereof. 
   
   
       18 - 40 . (canceled)

Join the waitlist — get patent alerts

Track US2009054527A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.